Sarah K. Tasian , Judith M. Boer , Monique L. den Boer
{"title":"从分子认识到儿童和青少年BCR::ABL1和abl型急性淋巴细胞白血病最佳治疗方案的床边","authors":"Sarah K. Tasian , Judith M. Boer , Monique L. den Boer","doi":"10.1016/j.ejcped.2025.100304","DOIUrl":null,"url":null,"abstract":"<div><div>This review aims to discuss similarities and dissimilarities between <em>BCR</em>::<em>ABL1</em>-rearranged (Philadelphia chromosome-positive [Ph+]) and ABL-class fusion-driven <em>BCR::ABL1</em>-like (Ph-like) acute lymphoblastic leukemia (ALL) in children and adolescents. Recent insights into the biology of these historically high-risk leukemias, modern laboratory diagnostics, current treatment approaches, potential causes of treatment failure, emerging new targeted therapies and immunotherapeutic approaches for patients will be discussed. While the primary focus of this review is upon children and adolescents with <em>BCR</em>::<em>ABL1</em>-positive and ABL-class ALL, extended knowledge from recent adult clinical trials will also be addressed.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"6 ","pages":"Article 100304"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents\",\"authors\":\"Sarah K. Tasian , Judith M. Boer , Monique L. den Boer\",\"doi\":\"10.1016/j.ejcped.2025.100304\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>This review aims to discuss similarities and dissimilarities between <em>BCR</em>::<em>ABL1</em>-rearranged (Philadelphia chromosome-positive [Ph+]) and ABL-class fusion-driven <em>BCR::ABL1</em>-like (Ph-like) acute lymphoblastic leukemia (ALL) in children and adolescents. Recent insights into the biology of these historically high-risk leukemias, modern laboratory diagnostics, current treatment approaches, potential causes of treatment failure, emerging new targeted therapies and immunotherapeutic approaches for patients will be discussed. While the primary focus of this review is upon children and adolescents with <em>BCR</em>::<em>ABL1</em>-positive and ABL-class ALL, extended knowledge from recent adult clinical trials will also be addressed.</div></div>\",\"PeriodicalId\":94314,\"journal\":{\"name\":\"EJC paediatric oncology\",\"volume\":\"6 \",\"pages\":\"Article 100304\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJC paediatric oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772610X25000923\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJC paediatric oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772610X25000923","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents
This review aims to discuss similarities and dissimilarities between BCR::ABL1-rearranged (Philadelphia chromosome-positive [Ph+]) and ABL-class fusion-driven BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL) in children and adolescents. Recent insights into the biology of these historically high-risk leukemias, modern laboratory diagnostics, current treatment approaches, potential causes of treatment failure, emerging new targeted therapies and immunotherapeutic approaches for patients will be discussed. While the primary focus of this review is upon children and adolescents with BCR::ABL1-positive and ABL-class ALL, extended knowledge from recent adult clinical trials will also be addressed.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
